Alnylam Pharma (ALNY) Tops Q1 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $227.28 +0.97%
EPS Growth %: -40.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -40.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.49), $0.35 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $243.02 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
